GSK stock holds support as investors await fresh data

GSK (GB0009252882) remains a London-listed large-cap health-care name, with its stock framed by the companys latest reported fundamentals and market valuation context. The group reported 2024 turnover of GBP 31.4 billion, adjusted operating profit of GBP 9.0 billion, and adjusted earnings per share of 156.3p, giving investors a dated baseline for the shares.

31.4 billion revenue base

GSK reported 2024 turnover of GBP 31.4 billion, up 8% at constant exchange rates, while adjusted operating profit reached GBP 9.0 billion. Adjusted earnings per share came in at 156.3p for 2024, a figure that gives the stock a concrete earnings reference point rather than a pure sentiment trade.

Those numbers matter because they frame how much operating leverage the market can still price into the next reporting cycle. The revenue figure and profit line also show that the company is not operating from a small base, which can make even modest margin changes relevant for valuation.

EPS at 156.3p

The 156.3p adjusted EPS for 2024 provides a clean comparison point against future half-year or full-year updates. The reported 8% constant-currency revenue growth also gives a quantified history check for the shares, which matters more than broad language about momentum.

For a stock like GSK, the market usually reacts less to narrative than to the next visible earnings step. That makes the combination of GBP 31.4 billion in turnover, GBP 9.0 billion in adjusted operating profit, and 156.3p in adjusted EPS the most useful current frame.

Shingles and vaccines

GSKs product mix still revolves around medicines and vaccines, with Shingrix remaining one of the companys most important franchises. The vaccine category is one reason the market continues to treat GSK as a cash-generating health-care group rather than a pure pipeline story.

That product exposure is relevant because vaccine revenue can be more visible than early-stage research programs. It also links directly back to the 2024 metrics, since a GBP 31.4 billion sales base and GBP 9.0 billion adjusted operating profit leave room for product-level execution to move the shares.

London listing context

GSK stock is listed in London and is commonly assessed through the companys earnings cadence, pipeline updates, and vaccine execution. The stock closing level was not included here because the most useful dated context available in this article is the companys reported 2024 financial base.

That still leaves investors with a usable picture: GBP 31.4 billion in turnover, GBP 9.0 billion in adjusted operating profit, and 156.3p adjusted EPS are the three figures that anchor the shares today.